Editor's Notes: * Akeso recently saw a big price jump due to a significant label update in China for one of its flagship products. Its robust R&D track record (impressive breakthrough with efficacy outperforming Merck's $30B blockbuster + inclusion of all 5 self-developed drugs in
Editor’s Notes * AI enthusiasm hasn’t cracked—but the cracks are being actively debated. On one hand, Nvidia and the broader AI stack (memory, storage, chips) still feel like the market’s gravitational center; on the other, the “AI bubble vs. new paradigm” argument is getting louder as valuations
Editor's Notes * Upcycle for metals & mining and industrial capex for supply chain migration can be beneficial tailwind for Komatsu. * Komatsu trades at a significant discount to CAT (peak valuation level), Deere, and Hitachi, with ~7% FCF yield, around 3-year mid point. While tariff impacts, regional exposure
Editor's Notes: * AI is still the whole story in the U.S.—and that’s both the bull case and the risk. Nvidia’s CES push (Vera Rubin + “physical AI”) keeps extending the narrative, but the fact that the Magnificent 7 drove the majority of S&P
Editor’s Notes * I’ll start with a confession: I’m a longtime Jordan Brand fan, so Nike is one of those companies I can’t look at purely through a spreadsheet. The brand still matters, culturally and globally—and that’s not something that disappears overnight. I do believe
Investment
Editor's Notes: * Defense stocks rise dominated yesterday's markets. Theme has not changed much yet, but starting to see new names entering our "large daily move" scan and profit-taking on overbought hot stocks (e.g. Jabil), which may signal some thematic narrative shift - namely
Editor's Notes: * Broader themes for early 2026 trading align with cautious mood in the US and improved sentiment for China / Japan. Starting to notice more price decline for SaaS in the US, as AI story turns negative for some of them. * Expect attention to continuing shifting from "
Editor's Notes * I mentioned Accenture as a potential target to look into after their Dec 18 earnings in a previous newsletter. Their strong performance vs. AI impact and soft IT cycle phase provided an interesting entry point - multiples close to 10-year low. * Below is a new experimental
Editor's Notes: * Macro theme remains the same as the past few days. Expect more AI debate / US overvaluation to dominate the markets in 2026. * Insider buying may signal some bullish view on Nike for 2026, given CEO, Tim Cook and another director's recent insider buying. Only
Editor's Notes: * Going into 2026, sentiment remains mixed and dominated by the debate around AI, with defense, metals & mining, the AI supply chain, JP MBOs, and China consumption on top of investors' minds. While valuations are rich, there is healthy skepticism, topical concentration, and plenty of
Investment
Editor's Notes: * Pfizer has been a popular "fallen angel" name (8x LTM / FWD P/E and 7% dividend yield), with Michael Burry's bullish call option disclosure in Nov putting it on many people's watchlist. * The heart of the issue is the transition
Investment
Editor's Notes: * AI is still leading, but expectations feel heavy. The market is optimistic, yet conversations are shifting from “AI = growth” to real constraints—optical bandwidth, transmission lines, and capex pressure. I’m still constructive, but I’m also more selective; not every AI-linked story deserves a